BIRTH OF A GLYCOTHERAPY FOR BREAST CANCER

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Breast cancer is a leading cause of cancer death in women, with current treatments causing severe side effects and drug resistance.
• Metastasis, particularly in triple-negative breast cancer (TNBC), significantly reduces survival rates, highlighting the need for more effective therapies.
• Existing treatments often fail to address cancer holistically, contributing to relapse and poor outcomes.

Purpose of the Study:

• To investigate the therapeutic potential of Tunicamycin-P, a pure N-glycosylation inhibitor, in treating various breast cancer subtypes.
• To evaluate the efficacy of Tunicamycin-P in inhibiting angiogenesis and tumor progression.
• To assess the safety and toxicity profile of Tunicamycin-P in preclinical models.

Main Methods:

• Utilized Tunicamycin-P to inhibit the N-glycosylation pathway in the endoplasmic reticulum by blocking N-acetylglucosaminyl 1-phosphate transferase (GPT) activity.
• Assessed the impact of Tunicamycin-P on in vitro and in vivo angiogenesis.
• Evaluated tumor progression in preclinical mouse models across multiple breast cancer subtypes.

Main Results:

• Tunicamycin-P demonstrated quantitative inhibition of both in vitro and in vivo angiogenesis.
• Significant inhibition of breast tumor progression was observed across multiple subtypes in preclinical models.
• Treatment with Tunicamycin-P exhibited "zero" toxicity in the tested models.

Conclusions:

• Tunicamycin-P effectively inhibits key pathways involved in breast cancer growth and metastasis.
• This novel Glycotherapy shows promise as a safe and effective treatment for all breast cancer subtypes, including TNBC.
• Tunicamycin-P is a potential candidate to replace current breast cancer therapeutics due to its broad efficacy and favorable safety profile.